ELSIE CREASON: Open Payments
NPI 1033611793 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$747 in 30 payments from 8 companies in 2025. Trend: 2023 $2,899 · 2024 $1,151 · 2025 $747
Food & beverage: $667Education: $80
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $256 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| ABBVIE INC. | 5 | $92 |
| E.R. Squibb & Sons, L.L.C. | 2 | $69 |
| Neurocrine BioSciences, Inc. | 3 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
| Lundbeck LLC | 1 | $14 |
Products named: AUSTEDO XR, REXULTI, VRAYLAR, COBENFY, INGREZZA, FANAPT, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across NV — which companies pay providers there.
